Lin Patrick

Chief Strategy Officer at struggling biotech buys shares near 52-week lows amid severe revenue decline.

Lin Patrick, the Chief Business-Strategy Officer at Processa Pharmaceuticals, purchased over 1,500 shares at heavily depressed levels, adding roughly a third to his existing holdings. This is noteworthy timing: the stock is trading well below its recent highs after declining sharply, and the company's fundamentals show severe distress with collapsing revenue and substantial losses. An officer's purchase at depressed valuations could signal either genuine conviction that the market has oversold the company or a forced move to demonstrate confidence during a difficult period. What matters most is whether Patrick's insider knowledge—given his strategy role—suggests the company has stabilized or has genuine catalysts ahead. Without visibility into recent developments, this purchase at depressed levels could be either a courageous contrarian bet or a hollow confidence-building gesture amid ongoing deterioration.

Chief Business Officer Patrick buys 1,369 shares of unprofitable PCSA at $2.97; stock down 74.1% from 52-week high; 5-insider cluster buy in 14 days.

Lin Patrick, Chief Business - Strategy Officer, purchased 1,369 shares at $2.97 on 2026-04-15, increasing his holdings by 40.8% from 3,356 to 4,725 shares. The company is unprofitable with net income of $-3,436,573.00 and zero revenue in the latest quarter, while trading at $3.10 today—down 74.1% from its 52-week high of $11.97. Patrick's historical timing at PCSA has been exceptional: his three prior measurable buys there returned 1614.7%, 2462.5%, and 2494.9% over 30 days respectively, with a perfect 90-day win rate across all three trades. The current buy occurs within a 14-day cluster in which 5 other insiders also purchased shares, suggesting coordinated conviction despite severe valuation deterioration and ongoing operational losses.

PCSA Chief Business Officer buys 1,603 shares at $2.54; prior 3 buys at this ticker all showed 90d gains of +643.6% to +2462.5%

Lin Patrick, Chief Business Officer–Strategy, purchased 1,603 shares at $2.54 on 2026-03-31, increasing his holdings by 91.4% to 3,356 shares total. His track record at Processa Pharmaceuticals is notably strong: all 3 prior open-market buys at this ticker were well-timed at the 90-day mark, with 90d returns ranging from +643.6% to +2462.5%. The current share price of $2.60 sits 78.3% below the 52-week high of $11.97, and a cluster of 8 other insiders bought within the past 14 days, suggesting coordinated confidence. However, the company remains unprofitable with zero revenue in its latest quarter and $-3.4M in net income, making this a speculative signal in a weak fundamental environment.

Chief Business Officer Lin Patrick bought 43,500 shares of PCSA at $0.80 amid -88.4% decline from 52-week high; 3 other insiders also bought in 14 days.

Lin Patrick, Chief Business - Strategy Officer, purchased 43,500 shares at $0.80 on 2025-01-27, accumulating his first holdings in PCSA. The timing is noteworthy: the current price of $14.81 is -88.4% from the 52-week high of $127.50, and the stock has declined -35.6% in the last 30 days and -48.7% over 90 days. His prior buys at this same ticker (2024-02-01 and 2024-01-31) both exhibited strong post-purchase returns of +2462.5% and +2494.9% on a 30-day basis. However, the company's latest quarter shows zero revenue and a net loss of $-3,384,703.00, with unprofitable full-year results; market capitalization stands at $48,383,440.64. The filing reveals a cluster pattern: 3 other insiders also bought within the past 14 days. The conjunction of steep valuation decline, officer accumulation, prior buy-side timing success at this ticker, and synchronized multi-insider purchasing activity warrants observation of whether this reflects opportunistic positioning or contrarian conviction in the face of deteriorating fundamentals.